TNF Pharmaceuticals (NASDAQ:TNFA) Stock Price Down 4.7% – Here’s What Happened

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) fell 4.7% during mid-day trading on Friday . The stock traded as low as $4.06 and last traded at $4.07. 387,168 shares were traded during trading, a decline of 89% from the average session volume of 3,511,287 shares. The stock had previously closed at $4.27.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of TNF Pharmaceuticals in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, TNF Pharmaceuticals has an average rating of “Sell”.

TNF Pharmaceuticals Price Performance

The firm’s 50 day moving average price is $4.47 and its 200-day moving average price is $5.90. The firm has a market cap of $7.52 million, a price-to-earnings ratio of -0.02 and a beta of 2.04.

TNF Pharmaceuticals Company Profile

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.